Spinifex Pharmaceuticals

Activities: Research & Development Pharmaceutical

Trending Articles

  1. OINDPs: Nosey about recent developments? OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
  2. Transforming healthcare with patient centricity In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  4. Compact process thermostat for efficient temperature control in the laboratory The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
  5. AviadoBio expands presence at Canary Wharf The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Research & Development

Spinifex Pharmaceuticals sold to Novartis

Novartis will continue to develop the company’s programmes to address neuropathic pain
Research & Development

Spinifex Pharmaceuticals makes two senior appointments in CMC team

Peter Spargo joins as SVP, CMC with Christine Richardson as Director, CMC and Nonclinical Project Manager
Research & Development

Spinifex Pharmaceuticals appoints neuroscience expert as Chief Medical Officer

Ronald Marcus joins the Australian-US biotechnology company
Regulatory

Neuropathic pain – EMA401

Pain that arises as a direct consequence of a lesion or disease affecting the somatosensory system is notoriously difficult to treat
Subscribe now